QR-110 demonstrated rapid and sustained improvement in vision in the majority of subjects, as measured by visual acuity and mobility course
QR-110 was well-tolerated with no serious adverse events
Reported positive interim analysis findings from Phase 1/2 Stellar trial of QR-421a for Usher syndrome and non-syndromic retinitis pigmentosa – study ongoing with dose expansion and escalation planned;Updated data from the Phase 1/2 InSight extension st
… Meeting of the Association for Research in Vision and Ophthalmology (ARVO) the company presented pre-clinical data … LCA 10 compound heterozygous patient cells and homozygous optic cups in a dose dependent manner. Based on this data, … QR-010 is designed to be self-administered via an optimized eFlow® Nebulizer (PARI Pharma GmbH). eFlow® is a …
… financial statements, the potential exercise of share options is not included in the diluted earnings per share … Due to the anti-dilutive nature of the outstanding options, basic and diluted earnings per share are equal in …
… Company’s novel RNA editing technologies Presented at the European Cystic Fibrosis Society (ECFS) conference on … Eluforsen is designed to be self-administered via an optimized eFlow ® Nebulizer (PARI Pharma GmbH). eFlow ® is a … financial statements, the potential exercise of share options is not included in the diluted earnings per share …
… ProQR will receive up to $7.5 million in funding for the development of QR-421a for the vision loss associated with … QR-421a study for Usher syndrome and the QR-313 study for dystrophic epidermolysis bullosa within the next twelve … Usher syndrome, which currently doesn’t have any treatment options. Looking out more broadly, our balance sheet funds …
… announced several presentations highlighting the Company’s proprietary Axiomer ® RNA editing technology platform at … the 8 th annual Oligonucleotide and Precision Therapeutics (OPT) Congress, March 13-14, 2023 in Boston, MA, U.S.; RNA …
Positive preliminary data from InSight extension study of sepofarsen for LCA10 reported – consistent with benefit seen in Phase 1/2 and building confidence in Phase 2/3 Illuminate trial;
Strategic convertible debt financing extends runway into 2023 if fully draw
… In November, the first patient was dosed in the Phase 1/2 open-label trial (PQ-110-001) to assess the safety, … six adults (≥ 18 years) who have LCA 10 due to one or two copies of the p.Cys998X mutation in the CEP290 gene. During … expertise in genetic retinal disease in the U.S. and Europe. The objectives of the trial include safety, …
… financial statements, the potential exercise of share options is not included in the diluted earnings per share … period. Due to the anti-dilutive nature of the outstanding options, basic and diluted earnings per share are equal in …